Skip to main content
Premium Trial:

Request an Annual Quote

Lucira Health Receives Health Canada Authorization for At-Home COVID-19, Flu Test

NEW YORK – Lucira Health announced on Thursday that it has received authorization under an interim order from Health Canada to market the Lucira COVID-19 & Flu Test for emergency use. 

The nucleic acid amplification test provides independent diagnoses for COVID-19, influenza A, and influenza B on the same portable platform as Lucira's COVID-19 test, which received Health Canada authorization in April 2021. The single-use test uses a shallow nasal swab and returns results in 30 minutes, the company said in a statement. 

The combination COVID-19 and influenza assay received CE marking in May. 

Distribution of the multiplex test in Canada will be prioritized, along with the current COVID-19 test, and it is available to institutions, agencies, and consumers, the Emeryville, California-based firm said.

The authorization "is expected to help Canadians accurately test at home in advance of flu season, keep more people out of the emergency departments, and provide a rapid treatment pathway," Lucira President and CEO Erik Engelson said in a statement. 

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.